

Risk prediction for poor outcome and death in hospital in-patients with COVID-19: derivation in Wuhan, China and external validation in London, UK

	-	OII III	Checklist flow	Done
Section/Topic Title and abstract	Item		Checklist Item	Page
Title and abstract	1	l	Identify the study as developing and/or validating a multivariable prediction model, the	
Title	1	D;V	target population, and the outcome to be predicted.	1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	5
Introduction			,	
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	6-7
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	6-7
Methods			Validation of the model of both.	
WELTIOUS		l	Describe the study design or source of data (e.g., randomized trial, cohort, or registry	
Source of data	4a	D;V	data), separately for the development and validation data sets, if applicable.	S2**
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	S2
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	S2
	5b	D;V	Describe eligibility criteria for participants.	S2
	5c	D;V	Give details of treatments received, if relevant.	NA
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	S3
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	NA
Predictors Sample size	7a	D;V	Clearly define all predictors used in developing or validating the multivariable prediction	S3
	7b	D;V	model, including how and when they were measured. Report any actions to blind assessment of predictors for the outcome and other	NA
	8	D;V	predictors. Explain how the study size was arrived at.	S2-3, S21-22
Sample Size			Describe how missing data were handled (e.g., complete-case analysis, single	32-3, 321-22
Missing data	9	D;V	imputation, multiple imputation) with details of any imputation method.	S4
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	S3
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	S4-6
	10c	V	For validation, describe how the predictions were calculated.	S6
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	S5-6
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	NA
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	S6
Development	12	V	For validation, identify any differences from the development data in setting, eligibility	S2-6
vs. validation			criteria, outcome, and predictors.	
Results			Describe the flow of participants through the study, including the number of participants	
Participants	13a	D;V	with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	9, S20
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	9, 17, S9, S16
	13c	V	For validation, show a comparison with the development data of the distribution of	9, 17
	14a	D	important variables (demographics, predictors and outcome). Specify the number of participants and outcome events in each analysis.	18, S13-15,
Model development			If done, report the unadjusted association between each candidate predictor and	S21
	14b	D	outcome.	S9
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	S10
	15b	D	Explain how to the use the prediction model.	NA
Model performance	16	D;V	Report performance measures (with Cls) for the prediction model.	20-21
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	NA
			Discussion	
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	12-13
Interpretation	19a	V	For validation, discuss the results with reference to performance in the development	12
	19b	D;V	data, and any other validation data. Give an overall interpretation of the results, considering objectives, limitations, results	13
			from similar studies, and other relevant evidence.	
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	13-14
Supplementary	1	l	Other information Provide information about the availability of supplementary resources, such as study	
information	21	D;V	protocol, Web calculator, and data sets.	12, S4
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	5